<p>Farther Finance Advisors LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度其對雅培（NYSE:ABT - 免費報告）的持股增加了 19.7%。該機構投資者在此期間購買了 6,486 股後，持有 39,491 股該醫療產品製造商的股票。Farther Finance Advisors LLC 在雅培的持股在最近一個季度末的價值為 5,371,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>為什麼雅培在 2025 年第二季度是一個買入機會：增長與收益</li>
</ul>
<p>其他大型投資者也買賣了該公司的股票。Hughes Financial Services LLC 在第一季度獲得了雅培的新股份，估值約為 27,000 美元。Abound Financial LLC 在第一季度購買了雅培的新股份，價值 28,000 美元。Elequin Capital LP 在第一季度獲得了雅培的新職位，價值 30,000 美元。Wormser Freres Gestion 在第四季度獲得了雅培的新股份，估值為 32,000 美元。最後，JCIC Asset Management Inc. 在第一季度購買了雅培的新股份，價值約 32,000 美元。75.18% 的股票由機構投資者持有。</p>
<h2>雅培股票上漲 1.2%</h2>
<p>週五，ABT 股票開盤價為 136.22 美元。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該股票的 50 日移動平均線為 130.47 美元，200 日移動平均線為 131.14 美元。公司的債務與股本比率為 0.25，速動比率為 1.30，流動比率為 1.82。公司的市值為 2370.9 億美元，市盈率為 17.07，PEG 比率為 2.58，貝塔值為 0.69。</p>
<ul>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 7 月 17 日星期四發佈了季度財報。該醫療產品製造商報告的季度每股收益為 1.26 美元，符合分析師的共識預期 1.26 美元。該公司在本季度的收入為 111.4 億美元，而分析師預期為 110.1 億美元。雅培的淨利潤率為 32.43%，股本回報率為 18.32%。該公司的季度收入同比增長 7.4%。在去年同期，該公司每股收益為 1.14 美元。雅培已將其 2025 財年的指導目標設定為 5.100-5.200 每股收益。2025 年第三季度的指導目標為 1.280-1.320 每股收益。整體來看，股票研究分析師預測雅培在當前年度的每股收益為 5.14。</p>
<h2>雅培宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 11 月 17 日星期一支付。10 月 15 日星期三的登記投資者將獲得每股 0.59 美元的分紅。除息日為 10 月 15 日星期三。這代表着每年 2.36 美元的分紅和 1.7% 的分紅收益率。雅培的派息比率目前為 29.57%。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>抗關税的雅培有望創下新高</li>
</ul>
<p>一些分析師最近對 ABT 股票發佈了報告。加拿大皇家銀行將雅培的目標價格從 145.00 美元上調至 147.00 美元，並在 7 月 15 日的研究報告中給予該公司 “跑贏大盤” 的評級。Evercore ISI 將雅培的目標價格從 140.00 美元上調至 145.00 美元，並在 7 月 8 日的研究報告中給予該股票 “跑贏大盤” 的評級。Leerink Partners 在 6 月 16 日的研究報告中開始覆蓋雅培股票。他們給予該公司 “市場表現” 的評級，目標價格為 143.00 美元。Raymond James Financial 將雅培股票的目標價格從 142.00 美元下調至 141.00 美元，並在 7 月 18 日的研究報告中對該股票設定了 “跑贏大盤” 的評級。最後，William Blair 在 7 月 17 日的研究報告中將雅培股票的評級提升至 “強力買入”。兩位分析師給予該股票 “強力買入” 評級，十五位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 145.22 美元。</p>
<p><strong>獲取我們關於 ABT 的最新報告</strong></p>
<h2>內部活動</h2>
<p>在其他消息中，首席財務官 Philip P. Boudreau 於 8 月 8 日星期五出售了 5,550 股公司的股票。股票以 134.55 美元的平均價格出售，總交易額為 746,752.50 美元。出售後，首席財務官在公司持有 51,003 股，價值約為 6,862,453.65 美元。此次交易使其持股減少了 9.81%。該交易已在向 SEC 的文件中披露，SEC 網站上可以訪問。公司內部人士持有該公司股票的 0.46%。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是雅培</li>
<li>交通運輸股票投資</li>
<li>卡特彼勒股票創下歷史新高——還有上漲空間嗎？</li>
<li>什麼是股息冠軍？如何投資於冠軍股票</li>
<li>伯克希爾支持的 Lennar 在第三季度業績疲軟後下滑</li>
<li>什麼是認沽期權成交量？</li>
<li>分析師對好時轉為看漲——百事可樂是下一個價值投資嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Farther Finance Advisors LLC 在第二季度將其在雅培（NYSE:ABT）的持股增加了 19.7%，目前擁有 39,491 股，價值 537 萬美元。該公司報告的季度每股收益為 1.26 美元，符合預期，收入為 111.4 億美元。雅培宣佈每股季度股息為 0.59 美元，收益率為 1.7%。分析師對雅培的共識評級為 “適度買入”，平均目標價為 145.22 美元。首席財務官 Philip P. Boudreau 最近出售了 5,550 股</p>

<p>Farther Finance Advisors LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 19.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,491 shares of the healthcare product maker's stock after purchasing an additional 6,486 shares during the period. Farther Finance Advisors LLC's holdings in Abbott Laboratories were worth $5,371,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Farther Finance Advisors LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度其對雅培（NYSE:ABT - 免費報告）的持股增加了 19.7%。該機構投資者在此期間購買了 6,486 股後，持有 39,491 股該醫療產品製造商的股票。Farther Finance Advisors LLC 在雅培的持股在最近一個季度末的價值為 5,371,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼雅培在 2025 年第二季度是一個買入機會：增長與收益</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the first quarter worth $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories in the 4th quarter valued at $32,000. Finally, JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the 1st quarter worth about $32,000. 75.18% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者也買賣了該公司的股票。Hughes Financial Services LLC 在第一季度獲得了雅培的新股份，估值約為 27,000 美元。Abound Financial LLC 在第一季度購買了雅培的新股份，價值 28,000 美元。Elequin Capital LP 在第一季度獲得了雅培的新職位，價值 30,000 美元。Wormser Freres Gestion 在第四季度獲得了雅培的新股份，估值為 32,000 美元。最後，JCIC Asset Management Inc. 在第一季度購買了雅培的新股份，價值約 32,000 美元。75.18% 的股票由機構投資者持有。</p>
</div><h2>Abbott Laboratories Stock Up 1.2%</h2>
<div class="lb-trans"><h2>雅培股票上漲 1.2%</h2>
</div><p>ABT stock opened at $136.22 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a fifty day moving average of $130.47 and a 200-day moving average of $131.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 2.58 and a beta of 0.69.</p>
<div class="lb-trans"><p>週五，ABT 股票開盤價為 136.22 美元。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該股票的 50 日移動平均線為 130.47 美元，200 日移動平均線為 131.14 美元。公司的債務與股本比率為 0.25，速動比率為 1.30，流動比率為 1.82。公司的市值為 2370.9 億美元，市盈率為 17.07，PEG 比率為 2.58，貝塔值為 0.69。</p>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 7 月 17 日星期四發佈了季度財報。該醫療產品製造商報告的季度每股收益為 1.26 美元，符合分析師的共識預期 1.26 美元。該公司在本季度的收入為 111.4 億美元，而分析師預期為 110.1 億美元。雅培的淨利潤率為 32.43%，股本回報率為 18.32%。該公司的季度收入同比增長 7.4%。在去年同期，該公司每股收益為 1.14 美元。雅培已將其 2025 財年的指導目標設定為 5.100-5.200 每股收益。2025 年第三季度的指導目標為 1.280-1.320 每股收益。整體來看，股票研究分析師預測雅培在當前年度的每股收益為 5.14。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣佈分紅</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 11 月 17 日星期一支付。10 月 15 日星期三的登記投資者將獲得每股 0.59 美元的分紅。除息日為 10 月 15 日星期三。這代表着每年 2.36 美元的分紅和 1.7% 的分紅收益率。雅培的派息比率目前為 29.57%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Tariff-Resistant Abbott Laboratories on Track for New Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>抗關税的雅培有望創下新高</li>
</ul>
</div><p>A number of analysts recently issued reports on ABT shares. Royal Bank Of Canada lifted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, July 15th. Evercore ISI upped their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, July 8th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a &#34;market perform&#34; rating and a $143.00 target price for the company. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, July 18th. Finally, William Blair raised shares of Abbott Laboratories to a &#34;strong-buy&#34; rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $145.22.</p>
<div class="lb-trans"><p>一些分析師最近對 ABT 股票發佈了報告。加拿大皇家銀行將雅培的目標價格從 145.00 美元上調至 147.00 美元，並在 7 月 15 日的研究報告中給予該公司 “跑贏大盤” 的評級。Evercore ISI 將雅培的目標價格從 140.00 美元上調至 145.00 美元，並在 7 月 8 日的研究報告中給予該股票 “跑贏大盤” 的評級。Leerink Partners 在 6 月 16 日的研究報告中開始覆蓋雅培股票。他們給予該公司 “市場表現” 的評級，目標價格為 143.00 美元。Raymond James Financial 將雅培股票的目標價格從 142.00 美元下調至 141.00 美元，並在 7 月 18 日的研究報告中對該股票設定了 “跑贏大盤” 的評級。最後，William Blair 在 7 月 17 日的研究報告中將雅培股票的評級提升至 “強力買入”。兩位分析師給予該股票 “強力買入” 評級，十五位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，平均目標價格為 145.22 美元。</p>
</div><p><strong>Get Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ABT 的最新報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席財務官 Philip P. Boudreau 於 8 月 8 日星期五出售了 5,550 股公司的股票。股票以 134.55 美元的平均價格出售，總交易額為 746,752.50 美元。出售後，首席財務官在公司持有 51,003 股，價值約為 6,862,453.65 美元。此次交易使其持股減少了 9.81%。該交易已在向 SEC 的文件中披露，SEC 網站上可以訪問。公司內部人士持有該公司股票的 0.46%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Transportation Stocks Investing</li>
<li>Caterpillar Stock Hits All-Time High—Is There More Room to Run?</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Berkshire-Backed Lennar Slides After Weak Q3 Earnings</li>
<li>What is Put Option Volume?</li>
<li>Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是雅培</li>
<li>交通運輸股票投資</li>
<li>卡特彼勒股票創下歷史新高——還有上漲空間嗎？</li>
<li>什麼是股息冠軍？如何投資於冠軍股票</li>
<li>伯克希爾支持的 Lennar 在第三季度業績疲軟後下滑</li>
<li>什麼是認沽期權成交量？</li>
<li>分析師對好時轉為看漲——百事可樂是下一個價值投資嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Farther Finance Advisors LLC 持有雅培公司價值 537 萬美元的股權